When a pharmaceutical patent expires, the first generic company to file an abbreviated new drug application with the US FDA earns 180 days of market exclusivity — a window worth hundreds of millions of dollars. Natco Pharma Limited, founded in Hyderabad in 1981, built an entire business model around winning that race. The company has filed more Paragraph IV patent challenges than almost any Indian pharmaceutical company of its size, turning patent law into a competitive weapon and oncology access into a global mission.
In the United States, patent protection for branded drugs can last twenty years or more. Generic companies that want to enter the market before patents expire must file a Paragraph IV certification — a legal assertion that the patents in question are invalid, unenforceable, or not infringed. The first generic applicant to file gets 180 days of exclusive generic sales, a period when no other generic competitor can enter.
Natco turned this mechanism into a repeatable strategy. The company invested in deep patent analysis capabilities and regulatory science, identifying high-value molecules where patent challenges had a reasonable chance of success. Unlike larger generic companies that spread resources across hundreds of filings, Natco focused on a smaller number of high-stakes challenges — fewer bets, but bigger payoffs when they worked.
The approach required patience. Paragraph IV challenges often involve years of litigation before a single dose of generic medicine reaches a patient. But when they succeed, the financial and public-health impact is significant: branded oncology drugs that cost thousands of dollars per month become available as generics at a fraction of the price.
No single product defines Natco’s Paragraph IV strategy more clearly than lenalidomide, marketed by Celgene (now Bristol-Myers Squibb) under the brand name Revlimid. Lenalidomide is a treatment for multiple myeloma — one of the most commercially successful oncology drugs in history, generating peak annual sales exceeding $12 billion globally.
Natco filed a Paragraph IV certification challenging Celgene’s patents on Revlimid and pursued an ANDA with the FDA. The resulting litigation culminated in a settlement that allowed Natco to launch a generic version of lenalidomide in the United States beginning in March 2022, initially under volume limitations that gradually increased through March 2025, and with an unlimited license from January 2026.
The Revlimid challenge was a watershed. It demonstrated that a mid-sized Indian pharmaceutical company could take on one of the world’s largest branded drug franchises through legal strategy and scientific rigour, and it transformed Natco’s revenue trajectory. Consolidated revenue grew from $234 million in FY 2022 to $534 million in FY 2025 — more than doubling in three years, driven substantially by generic lenalidomide sales in the US market.
Natco is the market leader in branded oncology medicines in India, with a portfolio spanning treatments for cancers of the blood, liver, kidney, lung, brain, breast, and ovary. The company’s domestic oncology franchise was built on the same principle as its US business — making expensive cancer treatments accessible at lower prices — but through branded generics rather than Paragraph IV challenges.
In 2012, Natco made global headlines when the Indian patent office granted it a compulsory licence to produce a generic version of Bayer’s kidney cancer drug sorafenib (Nexavar). The decision was one of the most significant in Indian pharmaceutical history, establishing that patent rights could be overridden when a life-saving drug was priced beyond the reach of patients who needed it.
Beyond oncology, Natco has expanded into cardiovascular, central nervous system, and anti-diabetic therapeutic areas. More recently, the company launched generic pomalidomide capsules in the US market in early 2026 through its partner Breckenridge Pharmaceutical — another major multiple myeloma treatment, extending the Revlimid playbook to the next generation of blood cancer drugs.
Natco operates across more than 50 countries, with nine manufacturing facilities and two R&D centres in India. The company’s facilities hold approvals from the US FDA, Health Canada, ANVISA (Brazil), WHO, and multiple other international regulatory authorities. Export formulations — principally to the United States, Canada, Brazil, and Europe — accounted for approximately 79% of FY 2025 revenue, with the domestic Indian market contributing the remaining 21%.
Natco operates nine manufacturing facilities across Telangana, Andhra Pradesh, and Tamil Nadu, with four registered with the US FDA. The company’s two dedicated R&D centres focus on complex generics development, process chemistry, and analytical method development. In FY 2025, the company employed approximately 3,300 people. Natco also maintains a US subsidiary, NATCO Pharma Inc., which supports regulatory filings, commercial partnerships, and distribution across North America.
Sources: Natco Pharma Annual Reports FY2021 through FY2025. Natco Pharma Earnings Presentations Q4 FY25. US FDA facility registration data and ANDA approval records. Celgene/BMS SEC filings (8-K, FY2015) regarding Revlimid settlement. Indian patent office records.